KALA BIO to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
KALA BIO to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
ARLINGTON, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that management will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, which is being held virtually. A pre-recorded fireside chat will be made available beginning on Tuesday, February 13, 2024 at 12:00 p.m. ET. Management will also be available for one-on-one meetings throughout the conference.
馬薩諸塞州阿靈頓，2024年2月6日（環球新聞專線）——致力於罕見和嚴重眼部疾病創新療法研究、開發和商業化的臨床階段生物製藥公司KALA BIO, Inc.（納斯達克股票代碼：KALA）今天宣佈，管理層將出席以虛擬方式舉行的奧本海默第34屆年度醫療保健生命科學會議。預先錄製的爐邊談話將於美國東部時間2024年2月13日星期二中午12點開始。管理層還將在整個會議期間參加一對一的會議。
To access the webcast and subsequent archived recording of the presentation, please visit the "Presentations" section of the KALA website at www.kalarx.com.
要訪問演示文稿的網絡直播和隨後的存檔錄像，請訪問 KALA 網站的 “演示” 部分，網址爲 www.kalarx.com。
About KALA BIO, Inc.
關於 KALA BIO, Inc.
KALA is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye. KALA's biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. KALA's lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. KPI-012 is currently in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing, for which it has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration. KALA is also targeting the potential development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases that threaten vision and has initiated preclinical studies to evaluate the potential utility of its MSC-S platform for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease. For more information on KALA, please visit www.kalarx.com.
KALA是一家臨床階段的生物製藥公司，致力於罕見和嚴重眼部疾病的創新療法的研究、開發和商業化。KALA 基於生物製劑的研究療法利用其專有的間充質幹細胞分泌組 (MSC-S) 平台。KALA 的主要候選產品 KPI-012 是人類 MSC-S，它含有許多人類衍生的生物因子，例如生長因子、蛋白酶抑制劑、基質蛋白和神經營養因子，有可能糾正角膜癒合受損，而角膜癒合受損是多種嚴重眼部疾病的潛在病因。KPI-012 目前正在臨床開發中，用於治療持續性角膜上皮缺損 (PCED)，這是一種罕見的角膜癒合受損疾病，已獲得美國食品藥品監督管理局的孤兒藥和快速通道認定。KALA 還着眼於 KPI-012 的潛在開發，用於治療邊緣幹細胞缺乏症和其他威脅視力的罕見角膜疾病，並已啓動臨床前研究，以評估其 MSC-S 平台對視網膜退行性疾病（例如色素性視網膜炎和斯塔加特病）的潛在效用。有關 KALA 的更多信息，請訪問 www.kalarx.com。
Investor Contact:
投資者聯繫人：
Hannah Deresiewicz
hannah.deresiewicz@sternir.com
212-362-1200
漢娜·德雷西維奇
hannah.deresiewicz@sternir.com
212-362-1200
譯文內容由第三人軟體翻譯。